Phase 1 N=8 Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Maximum Tolerable Dose (MTD) of Pazopanib — NA mg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=420 Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
Pertussis · Whooping Cough · Tetanus
Primary: The Number of Subjects Reporting Solicited Local and Systemic Adverse Events After Receiving Different Formulations of aP and TdaP Booster Vaccine — 30; 33; 32; 35…
Phase 1 N=20 A Study of MM-111 in Patients With Advanced, Refractory Her2 Amplified, Heregulin Positive Cancers
Her2 Amplified Solid Tumors · Metastatic Breast Cancer
Primary: Maximum Tolerated Dose (MTD) or Maximum Feasible Dose — NA mg/kg
Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Phase 1 N=25 Effects of Suvorexant in Patients With Chronic Obstructive Pulmonary Disease (MK-4305-032)
Insomnia
Primary: Mean Arterial Oxygen Saturation (SaO2) During Total Sleep Time — 93.38; 92.99 Percentage of Oxygen Saturation
Phase 1 N=64 A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)
Angina Pectoris · Coronary Heart Disease · Calcitonin Gene-related Peptide Receptor
Primary: Number of Participants With Clinical Adverse Events (AEs) — 7; 1; 5 Participants
Phase 1 N=60 Safety and Tolerability Trial of Aripiprazole IM Depot Treatment in Adult Subjects With Schizophrenia Stabilized on Oral Antipsychotics Other Than Aripiprazole
Schizophrenia
Primary: Number of Participants With Adverse Events (AE). — 35; 1 Participants
Phase 1 N=24 Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026)
Migraine Disorders
Primary: Time-weighted Mean Arterial Pressure (Sumatriptan With Telcagepant Versus Sumatriptan Alone) — 89.0; 87.5 mmHg
Phase 1 N=6 Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled Prucalopride Succinate in Volunteers
Healthy
Primary: Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC 0→∞) of Radiolabelled Prucalopride Succinate — 96.5 ng*h/ml
Phase 1 N=32 Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease
Alzheimer Disease
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 5; 3; 6; 3 participants
Phase 1 N=3 Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal
Healthy
Primary: Efficacy of Tattoo Removal Using Topical Imiquimod 5% Cream — 4.3; 2.7 percentage of tattoo pigment removed
Phase 1 N=26 Effects of Suvorexant in Participants With Obstructive Sleep Apnea (MK-4305-036)
Sleep Apnea
Primary: Mean Apnea-Hypopnea Index (AHI) — 17.07; 14.41 Events per hour
Phase 1 N=52 Nicardipine vs Esmolol Craniotomy Emergence
Brain Tumors
Primary: Failure of Drug to Control Systolic Blood Pressure (SBP) < 140 mmHg — 1; 11 participants
Phase 1 N=16 Pharmacokinetics of Suvorexant in Participants With Hepatic Insufficiency (MK-4305-017)
Insomnia · Hepatic Insufficiency
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Moderate Hepatic Insufficiency Participants…
Phase 1 N=16 Pharmacokinetics of Suvorexant in Participants With Impaired Renal Function (MK-4305-023)(COMPLETED)
Insomnia
Primary: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time Zero to Infinity (0-∞) After Single Dose Suvorexant: Severe Renal Impairment Participants Versus…